p.92 抽出テキスト

meta-analysis of randomized controlled trials. Front Cardiovasc Med 2022;9:1090102. https://doi.org/10.3389/fcvm.2022.1090102 847. Conen D, Ke Wang M, Popova E, Chan MTV, Landoni G, Cata JP, et al. Effect of colchicine on perioperative atrial fibrillation and myocardial injury after non-cardiac surgery in patients undergoing major thoracic surgery (COP-AF): an international randomised trial. Lancet 2023;402:1627–35. https://doi.org/10.1016/S0140-6736(23) 01689-6 848. Fragão-Marques M, Teixeira F, Mancio J, Seixas N, Rocha-Neves J, Falcão-Pires I, et al. Impact of oral anticoagulation therapy on postoperative atrial fibrillation outcomes: a systematic review and meta-analysis. Thromb J 2021;19:89. https://doi.org/10.1186/ s12959-021-00342-2 849. Neves IA, Magalhães A, Lima da Silva G, Almeida AG, Borges M, Costa J, et al. Anticoagulation therapy in patients with post-operative atrial fibrillation: systematic review with meta-analysis. Vascul Pharmacol 2022;142:106929. https://doi.org/10. 1016/j.vph.2021.106929 850. Daoud EG, Strickberger SA, Man KC, Goyal R, Deeb GM, Bolling SF, et al. Preoperative amiodarone as prophylaxis against atrial fibrillation after heart surgery. N Engl J Med 1997;337:1785–91. https://doi.org/10.1056/NEJM199712183372501 851. Yagdi T, Nalbantgil S, Ayik F, Apaydin A, Islamoglu F, Posacioglu H, et al. Amiodarone reduces the incidence of atrial fibrillation after coronary artery bypass grafting. J Thorac Cardiovasc Surg 2003;125:1420–5. https://doi.org/10.1016/S0022-5223(02)73292-3 852. Butt JH, Xian Y, Peterson ED, Olsen PS, Rorth R, Gundlund A, et al. Long-term thromboembolic risk in patients with postoperative atrial fibrillation after coronary artery bypass graft surgery and patients with nonvalvular atrial fibrillation. JAMA Cardiol 2018;3:417–24. https://doi.org/10.1001/jamacardio.2018.0405 853. Gialdini G, Nearing K, Bhave PD, Bonuccelli U, Iadecola C, Healey JS, et al. Perioperative atrial fibrillation and the long-term risk of ischemic stroke. JAMA 2014; 312:616–22. https://doi.org/10.1001/jama.2014.9143 854. Horwich P, Buth KJ, Legare JF. New onset postoperative atrial fibrillation is associated with a long-term risk for stroke and death following cardiac surgery. J Card Surg 2013; 28:8–13. https://doi.org/10.1111/jocs.12033 855. Devereaux PJ, Yang H, Yusuf S, Guyatt G, Leslie K, et al. Effects of extended-release metoprolol succinate in patients undergoing non-cardiac surgery (POISE trial): a randomised controlled trial. Lancet 2008;371:1839–47. https://doi.org/10.1016/S0140- 6736(08)60601-7 856. Hart RG, Diener HC, Coutts SB, Easton JD, Granger CB, O’Donnell MJ, et al. Embolic strokes of undetermined source: the case for a new clinical construct. Lancet Neurol 2014;13:429–38. https://doi.org/10.1016/S1474-4422(13)70310-7 857. Sanna T, Diener HC, Passman RS, Di Lazzaro V, Bernstein RA, Morillo CA, et al. Cryptogenic stroke and underlying atrial fibrillation. N Engl J Med 2014;370: 2478–86. https://doi.org/10.1056/NEJMoa1313600 858. Rubiera M, Aires A, Antonenko K, Lémeret S, Nolte CH, Putaala J, et al. European Stroke Organisation (ESO) guideline on screening for subclinical atrial fibrillation after stroke or transient ischaemic attack of undetermined origin. Eur Stroke J 2022;7:VI. https://doi.org/10.1177/23969873221099478 859. von Falkenhausen AS, Feil K, Sinner MF, Schönecker S, Müller J, Wischmann J, et al. Atrial fibrillation risk assessment after embolic stroke of undetermined source. Ann Neurol 2023;93:479–88. https://doi.org/10.1002/ana.26545 860. Gladstone DJ, Spring M, Dorian P, Panzov V, Thorpe KE, Hall J, et al. Atrial fibrillation in patients with cryptogenic stroke. N Engl J Med 2014;370:2467–77. https://doi.org/10. 1056/NEJMoa1311376 861. Wachter R, Gröschel K, Gelbrich G, Hamann GF, Kermer P, Liman J, et al. Holter-electrocardiogram-monitoring in patients with acute ischaemic stroke (Find-AF(RANDOMISED)): an open-label randomised controlled trial. Lancet Neurol 2017;16:282–90. https://doi.org/10.1016/S1474-4422(17)30002-9 862. Buck BH, Hill MD, Quinn FR, Butcher KS, Menon BK, Gulamhusein S, et al. Effect of implantable vs prolonged external electrocardiographic monitoring on atrial fibrillation detection in patients with ischemic stroke: the PER DIEM randomized clinical trial. JAMA 2021;325:2160–8. https://doi.org/10.1001/jama.2021.6128 863. Bernstein RA, Kamel H, Granger CB, Piccini JP, Sethi PP, Katz JM, et al. Effect of longterm continuous cardiac monitoring vs usual care on detection of atrial fibrillation in patients with stroke attributed to large- or small-vessel disease: the STROKE-AF randomized clinical trial. JAMA 2021;325:2169–77. https://doi.org/10.1001/jama.2021. 6470 864. Tsivgoulis G, Katsanos AH, Köhrmann M, Caso V, Perren F, Palaiodimou L, et al. Duration of implantable cardiac monitoring and detection of atrial fibrillation in ischemic stroke patients: a systematic review and meta-analysis. J Stroke 2019;21:302–11. https://doi.org/10.5853/jos.2019.01067 865. Sagris D, Harrison SL, Buckley BJR, Ntaios G, Lip GYH. Long-term cardiac monitoring after embolic stroke of undetermined source: search longer, look harder. Am J Med 2022;135:e311–7. https://doi.org/10.1016/j.amjmed.2022.04.030 866. Liantinioti C, Palaiodimou L, Tympas K, Parissis J, Theodorou A, Ikonomidis I, et al. Potential utility of neurosonology in paroxysmal atrial fibrillation detection in patients with cryptogenic stroke. J Clin Med 2019;8:2002. https://doi.org/10.3390/jcm8112002 867. Tsivgoulis G, Katsanos AH, Grory BM, Köhrmann M, Ricci BA, Tsioufis K, et al. Prolonged cardiac rhythm monitoring and secondary stroke prevention in patients with cryptogenic cerebral ischemia. Stroke 2019;50:2175–80. https://doi.org/10. 1161/STROKEAHA.119.025169 868. Favilla CG, Ingala E, Jara J, Fessler E, Cucchiara B, Messé SR, et al. Predictors of finding occult atrial fibrillation after cryptogenic stroke. Stroke 2015;46:1210–5. https://doi. org/10.1161/STROKEAHA.114.007763 869. Lip GY, Nielsen PB. Should patients with atrial fibrillation and 1 stroke risk factor (CHA2DS2-VASc score 1 in men, 2 in women) be anticoagulated? Yes: even 1 stroke risk factor confers a real risk of stroke. Circulation 2016;133:1498–503; discussion 1503. https://doi.org/10.1161/CIRCULATIONAHA.115.016713 870. Ricci B, Chang AD, Hemendinger M, Dakay K, Cutting S, Burton T, et al. A simple score that predicts paroxysmal atrial fibrillation on outpatient cardiac monitoring after embolic stroke of unknown source. J Stroke Cerebrovasc Dis 2018;27:1692–6. https://doi. org/10.1016/j.jstrokecerebrovasdis.2018.01.028 871. Kwong C, Ling AY, Crawford MH, Zhao SX, Shah NH. A clinical score for predicting atrial fibrillation in patients with cryptogenic stroke or transient ischemic attack. Cardiology 2017;138:133–40. https://doi.org/10.1159/000476030 872. Li YG, Bisson A, Bodin A, Herbert J, Grammatico-Guillon L, Joung B, et al. C(2) HEST score and prediction of incident atrial fibrillation in poststroke patients: a French nationwide study. J Am Heart Assoc 2019;8:e012546. https://doi.org/10.1161/JAHA.119. 012546 873. Haeusler KG, Gröschel K, Köhrmann M, Anker SD, Brachmann J, Böhm M, et al. Expert opinion paper on atrial fibrillation detection after ischemic stroke. Clin Res Cardiol 2018;107:871–80. https://doi.org/10.1007/s00392-018-1256-9 874. Dilaveris PE, Antoniou CK, Caiani EG, Casado-Arroyo R, Climent A, Cluitmans M, et al. ESC working group on e-cardiology position paper: accuracy and reliability of electrocardiogram monitoring in the detection of atrial fibrillation in cryptogenic stroke patients: in collaboration with the Council on Stroke, the European Heart Rhythm Association, and the Digital Health Committee. Eur Heart J Digit Health 2022;3:341–58. https://doi.org/10.1093/ehjdh/ztac026 875. Diener HC, Sacco RL, Easton JD, Granger CB, Bernstein RA, Uchiyama S, et al. Dabigatran for prevention of stroke after embolic stroke of undetermined source. N Engl J Med 2019;380:1906–17. https://doi.org/10.1056/NEJMoa1813959 876. Hart RG, Sharma M, Mundl H, Kasner SE, Bangdiwala SI, Berkowitz SD, et al. Rivaroxaban for stroke prevention after embolic stroke of undetermined source. N Engl J Med 2018;378:2191–201. https://doi.org/10.1056/NEJMoa1802686 877. Poli S, Meissner C, Baezner HJ, Kraft A, Hillenbrand F, Hobohm C, et al. Apixaban for treatment of embolic stroke of undetermined source (ATTICUS) randomized trial— update of patient characteristics and study timeline after interim analysis. Eur Heart J 2021;42:ehab724.2070. https://doi.org/10.1093/eurheartj/ehab724.2070 878. Vaidya VR, Arora S, Patel N, Badheka AO, Patel N, Agnihotri K, et al. Burden of arrhythmia in pregnancy. Circulation 2017;135:619–21. https://doi.org/10.1161/ CIRCULATIONAHA.116.026681 879. Lee MS, Chen W, Zhang Z, Duan L, Ng A, Spencer HT, et al. Atrial fibrillation and atrial flutter in pregnant women—a population-based study. J Am Heart Assoc 2016;5: e003182. https://doi.org/10.1161/JAHA.115.003182 880. Tamirisa KP, Elkayam U, Briller JE, Mason PK, Pillarisetti J, Merchant FM, et al. Arrhythmias in pregnancy. JACC Clin Electrophysiol 2022;8:120–35. https://doi.org/10. 1016/j.jacep.2021.10.004 881. Salam AM, Ertekin E, van Hagen IM, Al Suwaidi J, Ruys TPE, Johnson MR, et al. Atrial fibrillation or flutter during pregnancy in patients with structural heart disease: data from the ROPAC (Registry on Pregnancy and Cardiac Disease). JACC Clin Electrophysiol 2015;1:284–92. https://doi.org/10.1016/j.jacep.2015.04.013 882. Chokesuwattanaskul R, Thongprayoon C, Bathini T, O’Corragain OA, Sharma K, Prechawat S, et al. Incidence of atrial fibrillation in pregnancy and clinical significance: a meta-analysis. Adv Med Sci 2019;64:415–22. https://doi.org/10.1016/j.advms.2019. 07.003 883. Tamirisa KP, Dye C, Bond RM, Hollier LM, Marinescu K, Vaseghi M, et al. Arrhythmias and heart failure in pregnancy: a dialogue on multidisciplinary collaboration. J Cardiovasc Dev Dis 2022;9:199. https://doi.org/10.3390/jcdd9070199 884. Al Bahhawi T, Aqeeli A, Harrison SL, Lane DA, Skjøth F, Buchan I, et al. Pregnancy-related complications and incidence of atrial fibrillation: a systematic review. J Clin Med 2023;12:1316. https://doi.org/10.3390/jcm12041316 885. Regitz-Zagrosek V, Roos-Hesselink JW, Bauersachs J, Blomstrom-Lundqvist C, Cifkova R, De Bonis M, et al. 2018 ESC Guidelines for the management of cardiovascular diseases during pregnancy. Eur Heart J 2018;39:3165–241. https://doi.org/10.1093/ eurheartj/ehy340 886. Areia AL, Mota-Pinto A. Experience with direct oral anticoagulants in pregnancy—a systematic review. J Perinat Med 2022;50:457–61. https://doi.org/10.1515/jpm-2021- 0457 887. Ueberham L, Hindricks G. Anticoagulation in special patient populations with atrial fibrillation. Herz 2021;46:323–8. https://doi.org/10.1007/s00059-021-05042-1 888. Bateman BT, Heide-Jørgensen U, Einarsdóttir K, Engeland A, Furu K, Gissler M, et al. β-Blocker use in pregnancy and the risk for congenital malformations: an international cohort study. Ann Intern Med 2018;169:665–73. https://doi.org/10.7326/M18-0338 889. Butters L, Kennedy S, Rubin PC. Atenolol in essential hypertension during pregnancy. BMJ 1990;301:587–9. https://doi.org/10.1136/bmj.301.6752.587

ESC Guidelines                                                                                                                                                                                          3405

Downloaded from academic.oup.com/eurheartj/article/45/36/3314/7738779 by guest on 07 October 2026